Trial reportDepression and anxiety2025
Efficacy and Safety of Toludesvenlafaxine Hydrochloride Sustained-Release Tablets in Depression With Anhedonia: A Single-Arm, Multicenter Clinical Study.
San-Wang Wang, Wei-Feng Mi, Xiao-Nan Hao, Xiao-Xing Liu, Xin Wen, Min Zhao, Hai-Feng Jiang, Wen-Zheng Wang, Tao Li, Zhong-Lin Tan and 15 more
Abstract readClinical TrialMulticenter Study
In one paragraphTrial report in Depression and anxiety, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
25 authors.
Wei-Feng MiPeking University Sixth Hospital, Peking University Institute of Mental Health, NHC Key Laboratory of Mental Health (Peking University), National Clinical Research Center for Mental Disorders (Peking University Sixth Hospital), Beijing, China.ORCID 0000-0003-2561-9785 Xiao-Nan HaoPeking University Sixth Hospital, Peking University Institute of Mental Health, NHC Key Laboratory of Mental Health (Peking University), National Clinical Research Center for Mental Disorders (Peking University Sixth Hospital), Beijing, China.ORCID 0009-0000-6895-7245 Xiao-Xing LiuPeking University Sixth Hospital, Peking University Institute of Mental Health, NHC Key Laboratory of Mental Health (Peking University), National Clinical Research Center for Mental Disorders (Peking University Sixth Hospital), Beijing, China.ORCID 0000-0001-7592-0483 Xin WenPeking-Tsinghua Center for Life Sciences and PKU-IDG/McGovern Institute for Brain Research, Peking University, Beijing, China.ORCID 0000-0001-8904-1340 Min ZhaoShanghai Mental Health Center, Shanghai Jiao Tong University School of Medicine, Shanghai, China.ORCID 0000-0002-4551-043X Hai-Feng JiangShanghai Mental Health Center, Shanghai Jiao Tong University School of Medicine, Shanghai, China.ORCID 0000-0001-8499-2825 Wen-Zheng WangShanghai Mental Health Center, Shanghai Jiao Tong University School of Medicine, Shanghai, China.ORCID 0000-0002-4679-3590 Tao LiAffiliated Mental Health Centre and Hangzhou Seventh People's Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China.ORCID 0000-0003-3831-901X Zhong-Lin TanAffiliated Mental Health Centre and Hangzhou Seventh People's Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China.ORCID 0000-0003-4542-2875 Song ChenAffiliated Mental Health Centre and Hangzhou Seventh People's Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China.ORCID 0009-0005-3194-4412 Wen LvAffiliated Mental Health Centre and Hangzhou Seventh People's Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China.ORCID 0009-0005-5057-7654 Yu-Ping NingDepartment of Psychiatry, The Affiliated Brain Hospital of Guangzhou Medical University, Guangzhou, China.ORCID 0000-0002-5727-2782 Yan-Ling ZhouDepartment of Psychiatry, The Affiliated Brain Hospital of Guangzhou Medical University, Guangzhou, China.ORCID 0000-0002-8741-9394 Ying-Mei ChenDepartment of Psychiatry, The Affiliated Brain Hospital of Guangzhou Medical University, Guangzhou, China.ORCID 0009-0008-8321-9273 Xian-Cang MaDepartment of Psychiatry, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.ORCID 0000-0002-7826-305X Ying-Ying DongDepartment of Psychiatry, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.ORCID 0009-0001-1829-5789 Yun-Chun ChenDepartment of Psychiatry, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.ORCID 0009-0003-3583-7011 Hua ZhangDepartment of Psychiatry, Renmin Hospital of Wuhan University, Wuhan, China.
Funding
No grant is acknowledged in the PubMed record.
6 · The paper itselfAbstract
Toludesvenlafaxine hydrochloride sustained-release tablets, as China's first independently developed chemical Class 1 innovative drug with independent intellectual property rights for the treatment of depression and a new molecular entity, represent a novel triple reuptake inhibitor (TRI) with specific target selectivity for serotonin (5-HT), norepinephrine (NE), and dopamine (DA). This single-arm, multicenter clinical study aimed to evaluate the efficacy and safety of toludesvenlafaxine in alleviating anhedonia symptoms in patients with major depressive disorder (MDD). A total of 123 patients aged 18-65 years were enrolled between April 2023 and April 2024 and received an 8-week treatment with toludesvenlafaxine sustained-release tablets (80-160 mg/day). The primary efficacy endpoint was the change in the total score of the Dimensional Anhedonia Rating Scale (DARS) at weeks 2, 4, and 8. Significant improvements in DARS scores were observed, with mean changes from baseline of 8.4 (95% CI [6.4, 10.4],
Indexed as
AnhedoniaAntidepressive AgentsDesvenlafaxine SuccinateMajor Depressive DisorderOutcome Assessment, Health CareAdolescentAdultAgedDelayed-Action PreparationsFemaleHumansMaleMiddle AgedTabletsTreatment OutcomeYoung AdultAntidepressive AgentsDelayed-Action PreparationsDesvenlafaxine SuccinateTabletsanhedoniadepressionmulticenter clinical studytoludesvenlafaxine
Identifiers
PMID40365616
PMCPMC12069848
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390